Celltrion Takes Big Step On Xolair Biosimilar Journey
Phase I Trial For Omalizumab Candidate Began Last Year
Biosimilars major Celltrion has announced further progress on its biosimilar Xolair candidate, as it faces off against the likes of Glenmark to introduce global competition to Genentech/Novartis’ blockbuster cardiovascular biologic.
You may also be interested in...
Selexis and Generium have claimed the launch of an omalizumab biosimilar in Russia, with their Genolar version of Xolair marking the third biosimilar to be launched by the pair following development with Selexis’ SUREtechnology platform.
South Korea’s Celltrion has delivered a strong second quarter on the back of high-margin US sales, as its Truxima rituximab biosimilar recovered. The company is on track to launch at least one biosimilar every year by 2030. Meanwhile, the company and partner Icure have filed a donepezil patch with the Korean Ministry of Food and Drug Safety.
Cipla is to establish a new company with CDMO Kemwell Biopharma to develop and launch biosimilars for the global market, especially in the respiratory space, where Cipla has built a considerable presence for inhalation products.